D

    Dare Bioscience Inc (DARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.76
    +0.03 (+3.54%)

    Market Cap: $14.24M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    66%(25/38)
    Avg Surprise
    +7.46%
    Streak
    6 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.27 - $0.10
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.16-14.3%
    60d ago$-0.16-14.3%
    30d ago$-0.16-14.3%
    7d ago$-0.16-14.3%
    Current$-0.14
    Revenue Consensus
    $2M
    Range$0 - $6M
    3 analysts
    Dec 31, 2026
    EPS Consensus$-0.03
    Range$-0.23 - $0.31
    3 analysts
    Revenue Consensus
    $672340
    Range$-1705330 - $5M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.03---
    Sep 26EST
    		-$-0.14---
    Jun 26
    		$-0.20$-0.33+39.39%Beat+55.6%
    Mar 26
    		$-0.20$-0.30+33.33%Beat+60.0%
    Dec 25
    		$-0.10N/A+76.05%Beat+84.5%
    Sep 25
    		$-0.28$-0.40+30.00%Beat+49.1%
    Jun 25
    		$-0.45$-0.58+22.41%Beat+49.4%
    Mar 25
    		$-0.50$-0.58+13.79%Beat+40.5%
    Dec 24
    		$-0.65$-0.63-2.64%Miss-983.3%
    Sep 24
    		$-0.55$-0.71+22.54%Beat+49.1%
    Jun 24
    		$-0.89$-0.66-34.85%Miss+25.8%
    Mar 24
    		$-0.84$-0.72-16.67%Miss+22.2%
    Dec 23
    		$-0.06$-0.10+40.00%Beat+68.4%
    Sep 23
    		$-1.08$-1.20+10.00%Beat-12.5%
    Jun 23
    		$-1.20$-1.08-11.11%Miss-2100.0%
    Mar 23
    		$-1.08$-1.20+10.00%Beat-980.0%
    Dec 22
    		$-0.19$-0.14-35.71%Miss+91.2%
    Sep 22
    		$-0.96$-1.36+29.41%Beat+55.6%
    Jun 22
    		$0.06N/A+107.89%Beat+102.8%
    Mar 22
    		$-0.10$-0.14+28.57%Beat+95.2%
    Dec 21
    		$-2.16$-2.16+0.00%Beat-671.4%
    Sep 21
    		$-2.16$-2.10-2.86%Miss+25.0%
    Jun 21
    		$-2.16$-1.96-10.20%Miss+33.3%
    Mar 21
    		$-2.07$-2.96+30.07%Beat+4.2%
    Dec 20
    		$-0.28$-0.13-115.38%Miss-33.3%
    Sep 20
    		$-2.88$-2.22-29.73%Miss-20.0%
    Jun 20
    		$-3.24$-2.04-58.82%Miss+6.9%
    Mar 20
    		$-2.16$-3.92+44.90%Beat+33.3%
    Dec 19
    		$-0.21$-0.18-16.67%Miss+16.0%
    Sep 19
    		$-2.40$-2.48+3.23%Beat+13.0%
    Jun 19
    		$-3.48$-2.34-48.72%Miss+9.4%
    Mar 19
    		$-3.24$-3.96+18.18%Beat-268.2%
    Dec 18
    		$-0.25$-0.27+7.41%Beat+83.1%
    Sep 18
    		$-2.76$-2.96+6.76%Beat-736.4%
    Jun 18
    		$-3.84$-2.82-36.17%Miss-1820.0%
    Mar 18
    		$-0.88$-0.88+0.00%Beat+67.4%
    Dec 17
    		$-1.48N/A+52.26%Beat+7.5%
    Sep 17
    		$-0.33$0.00N/ABeat+90.8%
    Jun 17
    		$-0.20$0.00N/ABeat-
    Mar 17
    		$-2.70$-3.10+12.90%Beat-
    Dec 16
    		$-1.60N/A+52.24%Beat-
    Sep 16
    		$-3.60$-4.08+11.76%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.97EV/EBITDA-2.07x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-1583.00%
    ROE-2543.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.99xQuick Ratio0.99x
    Trading Statistics
    Beta1.05Avg Volume1.11M
    52-Week High$3.7852-Week Low$0.72

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.78
    SMA 20$1.03
    SMA 50$1.47
    SMA 200$1.84
    EMA 10$0.83
    EMA 20$0.98
    EMA 50$1.34
    EMA 200$1.84

    MACD

    Line: -0.21Signal: -0.21Hist: 0.00

    ADX

    ADX: 46.8+DI: 12.2-DI: 33.7

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down96.0
    PSAR$1.26

    Bollinger Bands

    Upper Band$1.62
    Lower Band$0.44
    %B Position11485%(Upper)
    Band Width0.27

    RSI (14-Day)

    Oversold
    27.8

    Momentum Oscillators

    Stoch %K2.4
    Stoch %D2.4
    Williams %R-95.4
    ROC (10d)-6.1%
    Momentum-0.05
    CCI (20d)-67.0
    MFI (14d)9.9

    Volatility Measures

    ATR (14d)$0.11(14.7%)
    StdDev (20d)0.30
    Hist Vol136.6%(High)

    Volume Flow

    VWAP$0.77
    OBV68.7M
    AD Line-86.7M
    CMF (20d)-0.448

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.5x
    VWMA (20d)$1.01

    Pivot Points

    R3$0.79
    R2$0.78
    R1$0.76
    Pivot Point$0.74
    S1$0.72
    S2$0.70
    S3$0.68

    Advanced Oscillators

    TSI-45.36
    Ultimate Osc26.4
    KST-440.97

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$187,546$152,455$1.02M$2,262$-21,172$0$-63,647$41,691$22,438$9,302$1.81M$1.00M
    Cost of Revenue$319,889$242,325$295,799$0$0$0$14.22M$0$0$0$21.56M$0
    Gross Profit$-132,343$-89,870$727,877$2,262$-21,172$0$-63,647$41,691$22,438$9,302$1.81M$1.00M
    Operating Expenses$2.84M$2.91M$2.20M$3.67M$3.81M$4.61M$5.32M$4.72M$7.38M$6.03M$6.98M$9.40M
    R&D$241,966$660,462$622,041$1.18M$1.43M$2.30M$3.34M$2.68M$4.93M$3.35M$3.80M$6.67M
    SG&A$2.59M$2.25M$1.58M$2.50M$2.38M$2.31M$2.00M$2.04M$2.45M$2.67M$3.15M$2.70M
    Operating Income$-2,967,980$-2,998,898$-1,471,268$-3,672,148$-3,827,800$-4,581,118$-5,388,197$-4,681,349$-7,359,466$-6,022,473$-5,171,460$-8,396,415
    Interest Income$0$0$0$0$0$0$0$0$20.38M$0$0$0
    Interest Expense$14,793$991$276,570$0$188,683$0$0$21,152$0$732,883$0$0
    Income Before Tax$-2,982,773$-2,999,889$-1,747,838$-3,562,766$-4,016,483$-4,378,307$-3,543,418$-4,702,501$12.91M$-6,755,356$-5,057,562$-8,299,096
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,982,773$-2,999,889$-1,441,718$-3,562,766$-4,016,483$-4,378,307$-5,506,398$-4,702,501$12.91M$-6,755,356$-5,057,562$-8,299,096
    EBITDA$-2,410,630$-2,445,246$-1,213,443$-2,956,609$-3,562,318$-4,202,665$-3,537,050$-4,692,759$-7,432,067$-6,743,919$-5,047,582$-8,289,836
    EBIT$-2,982,773$-2,999,889$-1,747,838$-3,562,766$-4,016,483$-4,378,307$-3,543,418$-4,702,501$-7,468,720$-6,755,356$-5,057,562$-8,299,096
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DARE

    News

    A women’s health biotech launches one product while preparing another to generate revenue

    Daré Bioscience (NASDAQ: DARE) is transitioning from a development-stage biotech to a commercial-stage women's health company, highlighted by the launch of Flora Sync LF5™ and preparations for DARE to PLAY™ Sildenafil Cream to begin generating revenue. CEO Sabrina Martucci Johnson discussed the company's commercial infrastructure build-out and pipeline advancements, including positive interim Phase 3 results for Ovaprene and DARE-HPV's move into Phase 2. The company anticipates key value-driving catalysts over the next 12-18 months.

    Stock Titan•8/25/26•
    Somewhat-Bullish

    Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

    Daré Bioscience's CEO, Sabrina Martucci Johnson, detailed the company's transition from a development-stage biotech to a commercial-stage entity during a Virtual Investor CEO Connect segment. The company is launching Flora Sync LF5™ and preparing DARE to PLAY™ Sildenafil Cream for revenue generation, while also advancing its pipeline with positive interim Phase 3 results for Ovaprene and DARE-HPV moving to Phase 2. Johnson highlighted the scalable commercial infrastructure and key catalysts expected to drive value over the next 12-18 months.

    GlobeNewswire•8/25/26•
    Bullish

    L1 Capital caps Dare Bioscience (DARE) stake at 9.99%

    L1 Capital Global Opportunities Master Fund, Ltd. has reported a beneficial ownership stake of 9.99% in Dare Bioscience, Inc. (DARE) through a Schedule 13G filing. This ownership comprises 2,028,885 common shares, including both common stock and Series A Warrants, limited to 9.99% of the outstanding shares. The filing indicates that L1 Capital has sole voting and dispositive power over these shares.

    Stock Titan•8/24/26•
    Neutral

    Dare Bioscience (NASDAQ: DARE) sets up $12.4M in potential warrant cash

    Dare Bioscience (NASDAQ: DARE) has filed a Form D for an exempt securities offering under Regulation D, Rule 506(b), indicating a potential to raise $12.4 million if all associated warrants are exercised. The offering includes warrants for over 8.7 million shares at $1.37 each and approximately 175,000 shares at $2.1235 each. While the offering's first sale date was August 17, 2026, no warrants have been exercised to date.

    Stock Titan•8/20/26•
    Somewhat-Bullish

    DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

    Sabrina Martucci Johnson, CEO of Daré Bioscience, has been recognized on Forbes' 2026 “50 Over 50: Innovation” list for her significant impact in women's health. The company, founded in 2015, is evolving from a clinical-stage biotechnology firm to a multi-product women's health company with commercial revenue opportunities and a differentiated development pipeline. This recognition highlights Daré Bioscience's commitment to addressing unmet needs in women's health through a diverse portfolio including contraception, sexual health, menopause, and infectious disease.

    GlobeNewswire•8/18/26•
    Bullish

    Frequently Asked Questions About DARE

    Does DARE pay dividends?
    Dare Bioscience Inc (DARE) does not currently pay a regular dividend.
    What is DARE's market cap?
    Dare Bioscience Inc (DARE) has a market capitalization of $14.24M with a current stock price of $0.76.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In